CN102920729A - Oligomerization mannuronic acid and application of medicinal salts of oligomerization mannuronic acid in leucopenia prevention medicines - Google Patents
Oligomerization mannuronic acid and application of medicinal salts of oligomerization mannuronic acid in leucopenia prevention medicines Download PDFInfo
- Publication number
- CN102920729A CN102920729A CN2012104390290A CN201210439029A CN102920729A CN 102920729 A CN102920729 A CN 102920729A CN 2012104390290 A CN2012104390290 A CN 2012104390290A CN 201210439029 A CN201210439029 A CN 201210439029A CN 102920729 A CN102920729 A CN 102920729A
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical salts
- oligomannuronic acid
- oligomannuronic
- oligomerization
- leukopenia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides oligomerization mannuronic acid and application of medicinal salts of oligomerization mannuronic acid in leucopenia prevention medicine. In in-vitro cell experiments, oligomerization mannuronic acid can obviously promote forming of colony-forming unit-granulocyte macrophage (CFU-GM), simultaneously can promote marrow stroma cells to breed and secrete CFU-GM and promote splenic lymphocytes to secrete interleukin-3. In vivo experiments further indicates that oligomerization mannuronic acid can obviously restrain reduction of white blood cells in mice caused by cyclophosphamide, increase the number marrow nucleated cell of the mice and promote forming of CFU-GM. Experiment results indicate that oligomerization mannuronic acid can be developed to be a clinical medicine capable of effectively preventing leucopenia.
Description
Technical field
The invention belongs to the marine drug field, be specifically related to the application in preparation control leukopenia disease drug of oligomannuronic acid or its pharmaceutical salts.
Background technology
Total white blood cells is 4 ~ 10 * 10 in the normal human blood
9/ L, when body is subject to the impact of medicine or other extraneous factors, quantity of leucocyte continues to be lower than 4 * 10 in the hyperamization liquid
9During/L, namely be called leukopenia (Leukopenia).Because granulocyte is leukocytic main component, so leukopenia is the most common is caused by granulocytopenia, when neutral granulocyte absolute value is lower than 1.8 ~ 2.0 * 10
9During/L, be called granulocytopenia (Neutropenia).
Leukopenia is serious side effects common in the tumor chemoradiotherapy, and it can cause the immunity degradation of body, patient's easy catching a cold, even bring out easily repeated infection.The medicine that is used for clinically treating leukopenia mainly contains berberine, leucogen, vitamin B
4DIYU SHENGBAI PIAN, batilol and inosine and colony stimulating factor etc., but the curative effect that this class medicine has is not satisfactory, exists expensive, patient is difficult to the drawbacks such as acceptance, therefore exploitation has definite curative effect, and is cheap, and the medicine of preventing and treating leukopenia that has no side effect be still clinically in the urgent need to.
Medicament research and development take sugar as the basis is one of the focus of biochemical drug research field in this century.The acidic oligosaccharide that marine polysaccharide particularly derives from Brown algae have the multiple biological activitys such as immunostimulant, antitumor, antiinflammatory, antioxidation, anticoagulant, antibiotic and infection (Ji et al, Int JBiology, 2011,3 (1), 74-86).Chinese scholars has been reported a large amount of about the preparation of Algin polysaccharide and derivant thereof and the patent of application facet (CN 1042361A, CN 1141927A, CN 1341664A).But also do not have at present about oligomannuronic acid at research and application report aspect the preparation control leukopenia disease drug.
Summary of the invention
For the shortcoming that curative effect of medication is imprecise and price is high for the treatment of leukopenia in the prior art, the invention provides the application in preparation control leukopenia disease drug of oligomannuronic acid or its pharmaceutical salts.Oligomannuronic acid provided by the invention has the effect of the murine interleukin minimizing that suppresses well caused by cyclophosphamide, and the quantity of the mouse bone marrow cells nucleated cell that can raise, promote Marrow Stromal Cells in Proliferation, promote marrow stromal cell secretory granule-huge assembly G-CSF (colony stimulatingfactor-granulocyte/macrophage that bites, GM-CSF), promote splenocyte secretion interleukin-3 (interleukin-3, IL-3), and can promote obviously that grain-huge biting is the formation of hemopoietic progenitor cell colony (colony forming unit-granulocyte/macrophage, CFU-GM) in the experiment in vivo and in vitro.
For achieving the above object, the present invention adopts following technical proposals to be achieved:
The invention provides the application in preparation control leukopenia disease drug of oligomannuronic acid or its pharmaceutical salts.
To further improvement in the technical proposal: the molecular skeleton of described oligomannuronic acid or its pharmaceutical salts is β-D-(1 → 4) the mannopyranose aldehydic acid that connects, weight average molecular weight is＜10kDa that its structural formula is shown in formula I;
The non reducing end saccharide residue can contain 4,5-position unsaturated double-bond, and its structural formula is shown in formula II:
R=H or Li in formula I and (II), Na, K, Ca, Mg pharmaceutical salts.
To further improvement in the technical proposal: described oligomannuronic acid or its pharmaceutical salts significantly increase the quantity of leucocyte of leukopenia mice.
To further improvement in the technical proposal: described oligomannuronic acid can increase the quantity of leucocyte of leukopenia mice in the 180mg/kg-540mg/kg dosage range.
To further improvement in the technical proposal: described oligomannuronic acid or its pharmaceutical salts significantly increase leukopenia mouse bone marrow cells nucleated cell quantity.
To further improvement in the technical proposal: described oligomannuronic acid significantly increases mouse bone marrow cells nucleated cell quantity in the 180mg/kg-540mg/kg dosage range.
To further improvement in the technical proposal: described oligomannuronic acid or its pharmaceutical salts obviously promote the growth of CFU-GM.
To further improvement in the technical proposal: described oligomannuronic acid or its pharmaceutical salts obviously promote the propagation of marrow stromal cell.
To further improvement in the technical proposal: described oligomannuronic acid or its pharmaceutical salts obviously promote the marrow stromal cell secrete GM-CSF, promote splenocyte secretion IL-3.
Compared with prior art, advantage of the present invention and good effect are: the present invention has proved that by experiment oligomannuronic acid can obviously increase the leukopenia murine interleukin quantity of caused by cyclophosphamide, improve bone marrow nucleated cell quantity, improve the formation of CFU-GM.In the experiment in vitro, oligomannuronic acid can obviously promote the propagation of marrow stromal cell, promotes the marrow stromal cell secrete GM-CSF, promotes splenocyte secretion IL-3, the formation that can obviously improve CFU-GM simultaneously.The present invention proves that by series of experiments oligomannuronic acid provided by the invention can be for the preparation of the medicine of preventing and treating leukopenia.
After reading the specific embodiment of the present invention by reference to the accompanying drawings, other characteristics of the present invention and advantage will become clearer.
Description of drawings
Fig. 1 shows oligomannuronic acid high-efficient liquid phase analysis collection of illustrative plates among the present invention.
Fig. 2 shows oligomannuronic acid infrared spectrogram among the present invention.
Fig. 3 shows oligomannuronic acid carbon-13 nmr spectra figure among the present invention.
Fig. 4 shows that the oligomannuronic acid vivo medicine-feeding reduces the effect (* 10 of disease among the present invention to the murine interleukin of caused by cyclophosphamide
9/ L).
Fig. 5 shows that the oligomannuronic acid vivo medicine-feeding is on the impact (* 10 of mouse bone marrow cells nucleated cell quantity among the present invention
6).
Fig. 6 shows that the oligomannuronic acid vivo medicine-feeding is on the impact of CFU-GM among the present invention.Grouping and the same Fig. 4 of administration situation.
Fig. 7 a shows the impact that the oligomannuronic acid treated in vitro forms normal bone marrow cells in mice CFU-GM among the present invention.
Fig. 7 b shows the microphotograph (* 100 times) of the impact that normal bone marrow cells in mice CFU-GM is formed of oligomannuronic acid treated in vitro empty matched group and 25ug/ml administration group among the present invention.
Fig. 8 shows that the oligomannuronic acid treated in vitro suppresses the impact that mice CFU-GM forms to cyclophosphamide among the present invention.
Fig. 9 shows that oligomannuronic acid is on the impact of Marrow Stromal Cells in Proliferation among the present invention.
Figure 10 shows that oligomannuronic acid is to the effect of bone marrow matrix secrete GM-CSF among the present invention.
Figure 11 shows that oligomannuronic acid is to the effect of splenocyte secretion IL-3 among the present invention.
The specific embodiment
Below in conjunction with the drawings and specific embodiments technical scheme of the present invention is described in further detail.
The preparation of embodiment 1, oligomannuronic acid
The present invention adopts the acid degradation method to prepare and separate the polymannuronate that obtains high molecular from the fucoidin Algin, further obtains oligomannuronic acid among the present invention through acid degradation or enzymatic degradation again.
The Algin water is mixed with the glue of concentration 2%, in the 0.5mol/L hydrochloric acid solution in 100 ℃ of hydrolysis 10 hours, behind the non-shock chilling, abandoning supernatant.To be precipitated and dissolved in 2%Na
2CO
3In the aqueous solution, regulate pH value to 2.85, the centrifugal precipitation of removing with dilute hydrochloric acid.Then add hydrochloric acid acid concentration to the system in the supernatant and reach 0.3mol/L, stir degraded 5 hours at 100 ℃.Then separate taking precipitate, will be precipitated and dissolved in 2%Na
2CO
3In the aqueous solution, with dilute hydrochloric acid adjust pH to 2.85, recentrifuge is removed precipitation.Then supernatant is added the long-pending ethanol of tetraploid and precipitate, it is formula I that precipitation is drying to obtain oligomannuronic acid.Can further this oligomannuronic acid be made 5% solution, add the reaction of alginate lyase liquid after 30 minutes, heat inactivation in 28 ℃.Then add the long-pending ethanol of tetraploid and precipitate and the while desalination, the oligomannuronic acid that precipitation is drying to obtain enzymolysis is formula II.
The oligomannuronic acid that the present invention makes or the molecular skeleton of its pharmaceutical salts are β-D-(1 → 4) the mannopyranose aldehydic acid that connects, weight average molecular weight is＜10kDa, the non reducing end saccharide residue can contain 4,5-position unsaturated double-bond, the concrete structure formula is as follows, R=H or Li in the formula, Na, K, Ca, Mg pharmaceutical salts.
Oligomannuronic acid high-efficient liquid phase analysis spectrogram as shown in Figure 1, prepared oligomannuronic acid weight average molecular weight is 5401, breadth coefficient (D) is 1.11.
The oligomannuronic acid infrared spectrum is as shown in Figure 2, and listed absworption peak ownership among the figure is as follows:
Oligomannuronic acid carbon-13 nmr spectra figure as shown in Figure 3, the 177.15ppm place is C6 position carboxyl carbon signal among the figure, the 101.83ppm place is the C1 signal, 79.67ppm locate the signal into C4,77.76ppm locate the signal into C5, the 73.24ppm place is the signal of C3, the 71.89ppm place is the C2 signal.
According to internationally recognized method, estimated it the murine interleukin of caused by cyclophosphamide reduced the effect of disease, and on cellular level preliminary study its mechanism of action.
Mouse peritoneal injection cyclophosphamide causes the leukopenia model, observe Oligomeric manna sugar aldehyde to the impact of quantity of leucocyte in the mouse peripheral blood, and measure mouse bone marrow cells nucleated cell quantity, having studied simultaneously the medicine vivo medicine-feeding is the impact of hemopoietic progenitor cell colony on mice grain-huge biting.
Concrete experimental technique is as follows: 60 of Kunming mouses are divided into 6 groups at random by body weight, Normal group, model control group, lithium carbonate positive controls, three dosage groups of oligomannuronic acid.Each treated animal gavage (ig) administration, normal group and model group give distilled water.Administration 9d, except Normal group, each organizes equal lumbar injection (ip) cyclophosphamide 50mg/kg, continuous 3d, last to cyclophosphamide after the 3rd day, carry out following experiment:
1) each treated animal tail point is got blood 20ul, adds the 1ml blood dilution liquid, measures hemogram on blood count, the results are shown in Figure 4.Among Fig. 4, except normal group, all the other each groups are all injected the cyclophosphamide modeling.Normal group and model group give water, and positive group gavage gives lithium carbonate, and dosage is 180mg/g; The dosage of basic, normal, high three the dosage groups of oligomannuronic acid is respectively 180mg/kg, 360mg/g and 540mg/kg.Vertical coordinate represents leukocytic quantity in the mouse peripheral blood among the figure.Compare ##, P＜0.01 with Normal group.Compare *, P＜0.05 with model group; *, P＜0.01.
As seen from Figure 4, ip in mice cyclophosphamide 50mg/kg, 3d can make the mouse peripheral blood leukocyte obviously descend continuously, compares with Normal group, and utmost point significant difference is arranged.Mice took oligomannuronic acid 14 days continuously, and three dosage groups can both leukocyte increasing reduce the quantity of leucocyte of disease mice, with model group significant difference and utmost point significant difference, P＜0.05 and P＜0.01 are arranged relatively.It can also be seen that from Fig. 4 the effect of oligomannuronic acid leukocyte increasing is better than the positive drug lithium carbonate.
2) after mice is put to death, put in 75% ethanol and sterilize, separate a side femur under the aseptic condition, cut off the femur two ends, draw the RPMI-1640 culture fluid with the 1ml asepsis injector, medullary cell is gone out, blow and beat into unicellularly with No. 4 syringe needles, at microscopically counting bone marrow nucleated cell number, the results are shown in Figure 5.Among Fig. 5, grouping and the same Fig. 4 of administration situation.Vertical coordinate represents mouse bone marrow cells nucleated cell quantity.Compare ##, P＜0.01 with Normal group.Compare * *, P＜0.01 with model group.
As can be seen from Figure 5, leukocytic variation tendency is consistent in the variation tendency of each treated animal bone marrow nucleated cell number and the peripheral blood.The bone marrow nucleated cell number of intact animal's a side femur reaches 10.69 * 10
6Individual, and behind the injection cyclophosphamide, bone marrow nucleated cell quantity obviously reduces in the model group animal femur, nucleated marrow cell population only is 4.49 * 10 in the side femur
6Individual, compare with normal group, utmost point significant difference is arranged.Three dosage groups of oligomannuronic acid can obviously increase mouse bone marrow cells nucleated cell quantity, compare with model group, utmost point significant difference are arranged, P＜0.01.
3) utilize external agar culture method to observe the oligomannuronic acid vivo medicine-feeding to the impact of mice CFU-GM.Kunming mouse is taken off cervical vertebra puts to death, put in 75% the ethanol behind the sterilization 5min, separate femur under the aseptic condition, cut off the femur two ends, draw the RPMI-1640 culture fluid with the 1ml asepsis injector, go out medullary cell, blow and beat into unicellular with No. 4 syringe needles, 1000 abandon culture fluid after leaving heart 5min, add the RPMI-1640 culture fluid and adjust cell to suitable concn.The results are shown in Figure 6.Among Fig. 6, vertical coordinate represents CFU-GM quantity.Compare ##, P＜0.01 with Normal group.Compare * *, P＜0.01 with model group.
As can be seen from Figure 6, the cyclophosphamide model group causes the hemopoietic system of mice to suffer damage, and hemopoietic progenitor cell quantity obviously reduces in its bone marrow, and the colony of generation and normal group compare, and quantity is few, and contained cell quantity also lacks than normal group in the single colony.Can obviously the raise quantity of CFU-GM of three dosage groups of oligomannuronic acid, with model group relatively, utmost point significant difference is arranged.And the effect of oligomannuronic acid low dose group is suitable with positive drug carbonic acid Role of lithium, and the effect of middle high dose group is better than lithium carbonate.
Embodiment 3, oligomannuronic acid treated in vitro are on the impact of CFU-GM
Utilize external agar culture method, studied the oligomannuronic acid treated in vitro, on the impact of normal bone marrow cells in mice and cyclophosphamide inhibition bone marrow cells in mice CFU-GM.
1) effect that normal bone marrow cells in mice CFU-GM is formed: get normal mouse, the conventional medullary cell that separates is got the RPMI-1640 culture fluid medullary cell is adjusted to concentration 1 * 10
6Ml
-1Carrying out colony cultivates.Experimental group adds respectively the medicine of variable concentrations, makes its final concentration be respectively 3.125ug/ml, 6.25ug/ml, 12.5ug/ml, 25ug/ml and 50ug/ml, and matched group adds the RPMI-1640 culture fluid with volume.Above-mentioned cultivating system is added in 24 orifice plates, every hole 0.5ml, each concentration is established 3 multiple holes, puts 37 ℃, 5%CO
2Cultivate in the incubator.After 5 days, carry out colony count under inverted microscope, all colonies that contains 50 above cells are a CFU-GM colony.The results are shown in Figure 7a and Fig. 7 b.Among Fig. 7 a, blank group is the matched group of not dosing; The dosage of five administration groups of oligomannuronic acid is respectively 3.125ug/ml, 6.25ug/ml, 12.5ug/ml, 25ug/ml and 50ug/ml, and vertical coordinate represents the quantity of CFU-GM colony.Compare * *, P＜0.01 with the blank group; *, P＜0.05.
Can find out from Fig. 7 a and Fig. 7 b, utilize the agar extracorporeal culture-ing, oligomannuronic acid can obviously promote the formation of CFU-GM colony, compares with the blank group, and significant difference is arranged.And arrive in the 25ug/ml scope 3.125, along with the increasing of drug level, effect also strengthens gradually, and effect reaches maximum during 25ug/ml.
2) cyclophosphamide is suppressed the effect that bone marrow cells in mice CFU-GM forms: get normal mouse, the conventional medullary cell that separates is got the RPMI-1640 culture fluid medullary cell is adjusted to concentration 1 * 10
6/ ml carries out colony and cultivates.Except Normal group, it is the cyclophosphamide of 100uM that other each groups add final concentration in the cultivating system.Experimental group adds respectively the medicine of variable concentrations, makes its final concentration be respectively 3.125ug/ml, 6.25ug/ml, 12.5ug/ml, 25ug/ml and 50ug/ml, and normal group and cyclophosphamide model group add the RPMI-1640 culture fluid with volume.Cultivate after 5 days, under inverted microscope, carry out colony count.The results are shown in Figure 8.Among Fig. 8, normal group is the matched group of not dosing; The CY group is not dosing, adds the model control group of cyclophosphamide (CY); The dosage of five administration groups of oligomannuronic acid is respectively 3.125ug/ml, 6.25ug/ml, 12.5ug/ml, 25ug/ml and 50ug/ml, adds simultaneously CY.Vertical coordinate represents the quantity of CFU-GM colony among Fig. 8.Compare ##, P＜0.01 with Normal group.Compare * *, P＜0.01 with the blank group; *, P＜0.05.
Each hemopoietic progenitor cell colony that the agar extracorporeal culture-ing forms derives from a cell.Granulocyte is that proliferation of hematopoietic progenitors differentiates by grain-huge biting, so the formation of In vitro culture observation CFU-GM, can reflect the size of Leukocytopoiesis ability.CFU-GM is more, illustrates that body has more hemopoietic progenitor cell, and also just having more cell to come Development And Differentiation is leukocyte.
As can be seen from Figure 8, the cyclophosphamide of 100uM can obviously suppress the formation of mouse bone marrow cells CFU-GM, compares with normal group, and significant difference is arranged.Can obviously the raise quantity of CFU-GM of oligomannuronic acid, with model group relatively, utmost point significant difference is arranged.And in the 25ug/ml scope, obvious dose-effect relationship is arranged at 3.125ug/ml, namely along with the increase of drug level, it promotes the effect of CFU-GM to strengthen gradually, reaches maximum effect during to 25ug/ml.
Utilize mtt assay, studied the impact of oligomannuronic acid on mouse bone marrow propagation.
Get 1 of mice, the conventional medullary cell that separates is adjusted cell concentration to 2 * 10 with the RPMI-1640 culture fluid of 20%FBS
6/ ml.Get 96 orifice plates, every hole adds 180ul cell suspension, adds respectively the oligomannuronic acid of 20ul variable concentrations again, make final concentration be respectively 3.125ug/ml, 6.25ug/ml, 12.5ug/ml, 25ug/ml and 50ug/ml, the blank group adds isopyknic culture fluid.Cell is placed 37 ℃, 5%CO
2Cultivate in the incubator after 7 days, mtt assay is measured the propagation of marrow stromal cell.The results are shown in Figure 9.Among Fig. 9, blank group is the matched group of not dosing; The dosage of oligomannuronic acid administration group is respectively 3.125ug/ml, 6.25ug/ml, 12.5ug/ml, 25ug/ml and 50ug/ml.Among Fig. 9, vertical coordinate represents the absorbance at 570nm place.Compare * *, P＜0.01 with the blank group; *, P＜0.05.
As can be seen from Figure 9, Oligomeric manna sugar aldehyde has obvious promotion proliferation function to mouse bone marrow, and except 3.125ug/ml concentration, other four concentration groups and blank group more all have notable difference.
Embodiment 5, oligomannuronic acid are to the effect of marrow stromal cell secrete GM-CSF
Utilize the ELISA method to measure the content of stromal cell secrete GM-CSF.
Get the RPMI-1640 culture fluid that contains 20% hyclone, it is 2 * 10 that medullary cell is adjusted to concentration
6/ ml.Get 6 orifice plates, every hole adds bone marrow cell suspension 1.8ml, the oligomannuronic acid that adds again the 0.2ml variable concentrations, make its final concentration be respectively 3.125ug/ml, 6.25ug/ml, 12.5ug/ml, 25ug/ml and 50ug/ml, matched group adds the culture fluid of equivalent, and each group is established respectively 3 multiple holes.Cell is placed 37 ℃, 5%CO
2After cultivating 8d in the incubator, draw culture supernatant, behind 4 ℃ of low-temperature centrifugations, get supernatant, with the content of GM-CSF in the ELISA kit measurement supernatant.The results are shown in Figure 10.Among Figure 10, normal group is the matched group of not dosing; The dosage of five administration groups of oligomannuronic acid is respectively 3.125ug/ml, 6.25ug/ml, 12.5ug/ml, 25ug/ml and 50ug/ml.Vertical coordinate represents the content of GM-CSF among Figure 10.Compare *, P＜0.05 with the blank group.
GM-CSF is that formation CFU-GM is necessary, and it can promote that grain-huge biting is the formation of hemopoietic progenitor cell colony.As can be seen from Figure 10, the oligomannuronic acid of 12.5ug/ml and 50ug/ml can obviously promote the stromal cell secrete GM-CSF, with the blank group significant difference is arranged relatively.And effect is the strongest when 25ug/ml.
Embodiment 6, oligomannuronic acid are secreted the effect of IL-3 to splenocyte
Utilize mtt assay to measure oligomannuronic acid to the effect of splenocyte secretion IL-3
The preparation of IL-3 sample: get Kunming mouse, the preparation splenocyte suspension.RPMI-1640 culture fluid with containing 10%FBS is adjusted to 1 * 10 with cell concentration
7/ ml.Get 24 orifice plates, every hole adds cell suspension 875ul, and adding final concentration is the ConA of 5ug/ml, the medicine that adds again variable concentrations makes final concentration be respectively 3.125ug/ml, 6.25ug/ml, 12.5ug/ml, 25ug/ml and 50ug/ml, blank group adds the culture fluid of equivalent.Culture plate is put 37 ℃, 5%CO
2Cultivated 72 hours in the incubator, collect supernatant ,-20 ℃ of preservations are the IL-3 testing sample.
The detection of IL-3 sample: get Kunming mouse, the conventional medullary cell that separates is adjusted cell concentration to 2 * 10 with the RPMI-1640 culture fluid that contains 10%FBS
6/ ml.Get 96 orifice plates, every hole adds 0.1ml cell suspension and 0.1ml IL-3 testing sample, and every sample is established 4 multiple holes.Culture plate is put 37 ℃, 5%CO
2Cultivated 7 days in the incubator, measure cell proliferation with mtt assay.The results are shown in Figure 11.Among Figure 11, normal group is the matched group of not dosing; The dosage of five administration groups of oligomannuronic acid is respectively 3.125ug/ml, 6.25ug/ml, 12.5ug/ml, 25ug/ml and 50ug/ml.Vertical coordinate represents absorbance among Figure 11.Compare *, P＜0.05 with the blank group; *, P＜0.01.
IL-3 claims again the polyclone colony stimulating factor, can promote the proliferation and differentiation of early stage germinal cell, promote the synthetic SCF of marrow stromal cell and IL-6 etc., and SCF and IL-6 can promote propagation and the change of hematopoietic stem cell, CFU-GM.As can be seen from Figure 11, oligomannuronic acid can obviously improve the ability of splenocyte secretion IL-3, compares with the blank group, and significant difference is arranged.And when 12.5ug/ml, act on the strongest.
To sum up, this experimental result shows that oligomannuronic acid can obviously suppress the minimizing of the murine interleukin of cyclophosphamide due to causing, improves the quantity of mouse bone marrow cells nucleated cell, promotes the propagation of mouse bone marrow.No matter Oligomeric manna sugar aldehyde is vivo medicine-feeding or treated in vitro, and normal mouse and cyclophosphamide are suppressed the formation of the CFU-GM of mice, and facilitation is all arranged.Oligomannuronic acid can promote the marrow stromal cell secrete GM-CSF, promotes splenocyte secretion IL-3.Above presentation of results, oligomannuronic acid is many-sided to the effect of hemopoietic system, and the effect of direct promotion proliferation of hematopoietic progenitors is namely arranged, and the indirectly effect by promoting that hematopoieticmicroenviron-ment improves the body hemopoietic function is arranged again.
Because the pharmaceutical salts of oligomannuronic acid has the backbone structure identical with oligomannuronic acid, so its pharmaceutical salts has the application in preparation control leukopenia disease drug identical with oligomannuronic acid.
Rule of origin of the present invention is in Sargassum, have the plurality of advantages such as aboundresources, with low cost and safety be high, prove that in animal level and cellular level it has the effect of better leukocyte increasing, a kind of effective clinically for developing, cheap, the drug provision that has no side effect theoretical foundation.
Above embodiment only is used for technical scheme of the present invention is described, but not limits it; Although with reference to previous embodiment the present invention is had been described in detail, for the person of ordinary skill of the art, still can make amendment to the technical scheme that previous embodiment is put down in writing, perhaps part technical characterictic wherein is equal to replacement; And these modifications or replacement do not make the essence of appropriate technical solution break away from the spirit and scope of the present invention's technical scheme required for protection.
Claims (9)
1. oligomannuronic acid or its pharmaceutical salts application in preparation control leukopenia disease drug.
2. oligomannuronic acid according to claim 1 or its pharmaceutical salts application in preparation control leukopenia disease drug, the molecular skeleton that it is characterized in that described oligomannuronic acid or its pharmaceutical salts is β-D-(1 → 4) the mannopyranose aldehydic acid that connects, weight average molecular weight is＜10 kDa, and its structural formula is shown in formula I;
The non reducing end saccharide residue can contain 4,5-position unsaturated double-bond, and its structural formula is shown in formula II:
R=H or Li in formula I and (II), Na, K, Ca, Mg pharmaceutical salts.
3. oligomannuronic acid according to claim 1 or its pharmaceutical salts application in preparation control leukopenia disease drug, it is characterized in that: described oligomannuronic acid or its pharmaceutical salts significantly increase the quantity of leucocyte of leukopenia mice.
4. oligomannuronic acid according to claim 3 or its pharmaceutical salts application in preparation control leukopenia disease drug, it is characterized in that: described oligomannuronic acid can increase the quantity of leucocyte of leukopenia mice in the 180mg/kg-540mg/kg dosage range.
5. oligomannuronic acid according to claim 1 or its pharmaceutical salts application in preparation control leukopenia disease drug, it is characterized in that: described oligomannuronic acid or its pharmaceutical salts significantly increase leukopenia mouse bone marrow cells nucleated cell quantity.
6. oligomannuronic acid according to claim 5 or its pharmaceutical salts application in preparation control leukopenia disease drug, it is characterized in that: described oligomannuronic acid significantly increases mouse bone marrow cells nucleated cell quantity in the 180mg/kg-540mg/kg dosage range.
7. oligomannuronic acid according to claim 1 or its pharmaceutical salts application in preparation control leukopenia disease drug, it is characterized in that: described oligomannuronic acid or its pharmaceutical salts obviously promote the growth of CFU-GM.
8. oligomannuronic acid according to claim 1 or its pharmaceutical salts application in preparation control leukopenia disease drug, it is characterized in that: described oligomannuronic acid or its pharmaceutical salts obviously promote the propagation of marrow stromal cell.
9. oligomannuronic acid according to claim 1 or its pharmaceutical salts application in preparation control leukopenia disease drug, it is characterized in that: described oligomannuronic acid or its pharmaceutical salts obviously promote the marrow stromal cell secrete GM-CSF, promote splenocyte secretion IL-3.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210439029.0A CN102920729B (en) | 2012-11-06 | 2012-11-06 | Application of oligomerization mannuronic acid and medicinal salts of oligomerization mannuronic acid in preparing medicine for leucopenia prevention |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210439029.0A CN102920729B (en) | 2012-11-06 | 2012-11-06 | Application of oligomerization mannuronic acid and medicinal salts of oligomerization mannuronic acid in preparing medicine for leucopenia prevention |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102920729A true CN102920729A (en) | 2013-02-13 |
| CN102920729B CN102920729B (en) | 2014-02-26 |
Family
ID=47635754
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210439029.0A Active CN102920729B (en) | 2012-11-06 | 2012-11-06 | Application of oligomerization mannuronic acid and medicinal salts of oligomerization mannuronic acid in preparing medicine for leucopenia prevention |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102920729B (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103405468A (en) * | 2013-08-16 | 2013-11-27 | 中国海洋大学 | Use of low-molecular weight oligomannuronate in preparation of drug or health care product for preventing or treating Parkinson's disease |
| CN104489356A (en) * | 2014-12-15 | 2015-04-08 | 青岛海洋生物医药研究院股份有限公司 | Application of oligomerization mannuronic acid in preparation of feed additive |
| CN106008613A (en) * | 2015-03-27 | 2016-10-12 | 全南大学校产学协力团 | Non-reducing-end Unsaturated Mannuronic Acid Oligosaccharides and Composition comprising the same as Active Ingredient |
| WO2018119770A1 (en) * | 2016-12-28 | 2018-07-05 | 深圳大学 | Use of seleno-polymannuronate |
| CN112592412A (en) * | 2020-12-02 | 2021-04-02 | 青岛海洋生物医药研究院股份有限公司 | A fucosan sulfate and its application in preparing medicines and functional products for preventing and treating leukopenia |
-
2012
- 2012-11-06 CN CN201210439029.0A patent/CN102920729B/en active Active
Non-Patent Citations (1)
| Title |
|---|
| 李海花等: "低聚甘露糖醛酸免疫调节作用实验研究", 《中国海洋药物》 * |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103405468A (en) * | 2013-08-16 | 2013-11-27 | 中国海洋大学 | Use of low-molecular weight oligomannuronate in preparation of drug or health care product for preventing or treating Parkinson's disease |
| CN104489356A (en) * | 2014-12-15 | 2015-04-08 | 青岛海洋生物医药研究院股份有限公司 | Application of oligomerization mannuronic acid in preparation of feed additive |
| CN106008613A (en) * | 2015-03-27 | 2016-10-12 | 全南大学校产学协力团 | Non-reducing-end Unsaturated Mannuronic Acid Oligosaccharides and Composition comprising the same as Active Ingredient |
| US10272100B2 (en) | 2015-03-27 | 2019-04-30 | Industry Foundation Of Chonnam National University | Non-reducing end unsaturated mannuronic acid oligosaccharides and compositions containing same as active ingredient |
| CN106008613B (en) * | 2015-03-27 | 2019-11-05 | 全南大学校产学协力团 | The unsaturated type mannuronic acid oligosaccharide of non reducing end and the composition comprising it as effective component |
| WO2018119770A1 (en) * | 2016-12-28 | 2018-07-05 | 深圳大学 | Use of seleno-polymannuronate |
| CN112592412A (en) * | 2020-12-02 | 2021-04-02 | 青岛海洋生物医药研究院股份有限公司 | A fucosan sulfate and its application in preparing medicines and functional products for preventing and treating leukopenia |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102920729B (en) | 2014-02-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102920729B (en) | Application of oligomerization mannuronic acid and medicinal salts of oligomerization mannuronic acid in preparing medicine for leucopenia prevention | |
| US20160151435A1 (en) | Pharmaceutical composition adjuvant to chemotherapy drugs and applications thereof | |
| EP3023104B1 (en) | Recombinant ganoderma lucidum immunomodulatory protein (rlz-8) for use in treating melanoma | |
| CN109320570A (en) | A kind of icariside I class compound, derivative, officinal salt and application | |
| KR20120069221A (en) | Bee venom composition | |
| CN105520934A (en) | Application of micheliolide dimethylamine | |
| CN101212963B (en) | The use of chlorogenic acid in the manufacture of medicaments for increasing the effect of bone marrow cells | |
| CN106389477B (en) | A kind of preparation method and application of the full cellular plant oil extract of Gordonia terrae | |
| CN112891362B (en) | Pharmaceutical composition for treating sepsis and application thereof | |
| CN101695485B (en) | Use of chlorogenic acid in preparing medicament for treating thrombocytopenia and anemia | |
| CN110327317B (en) | Application of alkannin in preparing medicine for resisting rotavirus infection | |
| CN111358782A (en) | Application of imipenem in preparation of medicine for treating inflammatory storm caused by infectious diseases | |
| CN109966289A (en) | Application of the dephnetin in anti-chicken coccidiasis | |
| CN113181222B (en) | Application of extracellular polysaccharide metabolite of cryptococcus lactis in preparation of antiviral drugs | |
| CN115154422B (en) | CD44 targeting and ROS response nano micelle pharmaceutical composition, and preparation method and application thereof | |
| CN103948614B (en) | The pharmaceutical applications of otoginsenoside and salt thereof | |
| CN117045639B (en) | Pharmaceutical composition for treating gastric cancer and application thereof | |
| CN112251402B (en) | Protein peptide, freeze-dried powder, oral liquid and preparation method thereof | |
| CN104758329B (en) | It is a kind of to be used to prevent Chinese medicine composition of chicken coccidiasis and preparation method thereof | |
| CN104873513B (en) | A kind of pharmaceutical composition and detection method for suppressing lung carcinoma cell transfer | |
| CN104887681B (en) | A kind of composition of medicine and detection method for suppressing lung carcinoma cell transfer | |
| CN113813373A (en) | Medicine for repairing intestinal mucosa and improving mucosal immunity and preparation method thereof | |
| CN117771377A (en) | Traditional Chinese medicine-containing serum conjugate and preparation method and application thereof | |
| Handayani Idrus et al. | Achras Zapota L Extract Reduces Levels of Soluble Tumor Necrosis Alpha (TNF-a) in Salmonella typhi Infected Animals | |
| CN101695486B (en) | Use of chlorogenic acid in preparing medicament for treating marrow fibrillation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20151103 Address after: 266071 Hongkong East Road, Laoshan District, Shandong, China, No. 23, No. Patentee after: Qingdao Ocean University of China Holdings Limited Address before: 266003 Shandong province Qingdao City fish Road No. 5 Patentee before: Ocean University of China |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20160520 Address after: 266071 Hongkong East Road, Laoshan District, Shandong, China, No. 23, No. Patentee after: Qingdao Haiyang biological medicine academy limited company Address before: 266071 Hongkong East Road, Laoshan District, Shandong, China, No. 23, No. Patentee before: Qingdao Ocean University of China Holdings Limited |